

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Boesen 1



Section 1. Identifying Inform	nation					
Given Name (First Name) Magnus Spangsberg	Surname (Last Name) Boesen	3. Date 28-October-2013				
4. Are you the corresponding author?						
5. Manuscript Title Onset Symptoms in Paediatric Multiple Sclerosis: a Retrospective Analysis						
6. Manuscript Identifying Number (if you know it) I dont have it						
Section 2. The Work Under C	onsideration for Publication					
	eive payment or services from a third party (government, cog g but not limited to grants, data monitoring board, study d est? Yes V No					
Section 3. Relevant financial	activities outside the submitted work.					
Place a check in the appropriate boxes of compensation) with entities as descr	in the table to indicate whether you have financial re ibed in the instructions. Use one line for each entity; port relationships that were present during the 36 i	add as many lines as you need by				
Section 4. Intellectual Proper	rty Patents & Copyrights					
	ned, pending or issued, broadly relevant to the work	? ☐ Yes ✓ No				

Boesen 2



Section 5.					
Section 5.	Relationships not covered above				
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?				
Yes, the following relationships/conditions/circumstances are present (explain below):					
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest				
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.				
Section 6.	Disclosure Statement				
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box				

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Boesen 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



9	Section 1. Identifying Inform	ation					
	. Given Name (First Name) inn	2. Surname (Last Name) Sellebjerg		3. Date 02-January-2013			
4.	. Are you the corresponding author?	Yes ✓ No	Corresponding Author Magnus Spangsberg				
	. Manuscript Title Onset Symptoms in Paediatric Multiple :	Sclerosis: a Retrospective	Analysis				
	. Manuscript Identifying Number (if you kn IFL-12-13-0728	ow it)					
	Section 2. The Work Under Consideration for Publication						
ar st	id you or your institution at any time receiny aspect of the submitted work (including atistical analysis, etc.)? re there any relevant conflicts of intere	but not limited to grants, da			tc.) for		
9	Section 3. Relevant financial a	activities outside the s	submitted work.				
oi cl A	lace a check in the appropriate boxes in f compensation) with entities as descril licking the "Add +" box. You should represent there any relevant conflicts of intere	bed in the instructions. Use ort relationships that were st? Yes No	se one line for each ent	ity; add as many lines as you nee	ed by		
lf	yes, please fill out the appropriate info	rmation below.					
Na	ame of Entity	Grant	n-Financial Other?	Comments			
Biog	gen Idec and Novartis		F	Research grants from Biogen Idec			



Bayer, Biogen Idec, Genzyme, Merck, Novartis, Sanofi-Aventis, Schering Plough and Teva		✓			Received honoraria for participation in scientific advisory boards for Biogen Idec, Genzyme, Merck, Novartis, Sanofi-Aventis and Teva and serving as consultant for Biogen Idec. Received support for congress participation from Biogen Idec, Novartis, Sanofi Aventis and Teva. Received speaker honoraria from Bayer, Biogen Idec, Genzyme, Merck, Novartis, Sanofi-Aventis and Schering-Plough.	
Merck and Multiple Sclerosis and Related Disorders			√	V	Served on the steering committee of a clinical trial sponsored by Merck. Section editor on Multiple Sclerosis and Related Disorders.	
Section 4. Intellectual Proper						
Section 5. Polationships not	·	_	ed, broadly releva	nt to the	work? Yes 🗸 No	
Are there other relationships or activitie potentially influencing, what you wrote	s that read	ders could _l		influence	ed, or that give the appearance of	
Yes, the following relationships/con						
At the time of manuscript acceptance, jo On occasion, journals may ask authors t					ssary, update their disclosure statements. relationships.	
Section 6. Disclosure Stateme	ent					
Based on the above disclosures, this for below.	m will auto	omatically (generate a disclos	sure state	ement, which will appear in the box	
Dr. Sellebjerg reports grants from Bioge Novartis, Sanofi-Aventis, Schering Plou Related Disorders, outside the submitt	gh and Te		•			



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Blinkenberg 1



Section 1. Id	entifying Inform	nation					
Given Name (First Notes) Morten	ame)	2. Surnar Blinkenb	name (Last Name) 3. Date nberg 01-January-2014				
4. Are you the corresponding author?							
5. Manuscript Title Onset Symptoms in Paediatric Multiple Sclerosis: a Retrospective Analysis							
6. Manuscript Identifying Number (if you know it)							
Section 2. Th							
Th	e Work Under C	onsiderat	tion for Publi	cation			
	itted work (including ?	but not lim				commercial, private founc design, manuscript prepa	
Section 3. Re	levant financial	activities	outside the	submitted	work.		
of compensation) wi	th entities as descripox. You should report the conflicts of interest.	ibed in the port relation est? (\square)`	instructions. Usonships that we Yes No	se one line fo	or each entity	relationships (regardles r; add as many lines as y months prior to publ	ou need by
Name of Entity		Grant?	2	n-Financial upport	Other? Co	omments	
Biogen Idec			√				
Merck Serono			✓				
Novartis			✓				
Sanofi Aventis			✓				
Teva Denmark			✓				
Genzyme			✓				

Blinkenberg 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume No
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Blinkenberg reports personal fees from Biogen Idec, personal fees from Merck Serono, personal fees from Novartis, personal fees from Sanofi Aventis, personal fees from Teva Denmark, personal fees from Genzyme, outside the submitted work; .

Evaluation and Feedback

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$

Blinkenberg 3